B
Biosplice Therapeutics
Medical research and development for tissue-level regeneration
At a glance
- Founded
- 2008
- Headquarters
- San Diego, United States
- Sector
- Biotech & Life Sciences
- Power Law
- Decacorn$10B+ valuation tier
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
- EVEsas Ventures
Series A3 investors entered at this stage
- SGStarling group
- PVPolar Light Ventures
- VPVickers Venture Partners
Series B and later6 investors entered at this stage
- CCChristian Cadeo
- SGSymbiosis Group
- EMEventide Asset Management
- COCem Ortabaş
- AFaMoon Fund
- VMVerition Fund Management
Ownership
Estimated cap table from Dealroom's shareholder data — share of equity by holder. Stakes as last recorded by Dealroom (2026). Percentages are indicative.
Some investors are hidden on this public profile. See the full cap table on Dealroom →
Source: Dealroom Talent Intelligence.
Global footprint
team presence
across markets
Patents
70 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
Market sentiment
An AI-synthesised read of the highest-engagement posts about Biosplice Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Biosplice Therapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.